InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Discover the full record of transactions filed by Christian Chavy, Independent Director. Officer active across 1 companies, notably Abionyx Pharma. In total, 3 disclosures have been recorded. Total volume traded: €67k. The latest transaction was disclosed on 18 December 2025 — Cession. Regulator: AMF. All data is openly available.
Declarations3 total
€33,30010,000 shares@ €3.330.025% mcap17.8% of flow
ActionEuronext Paris
2025DD1085361·
€33,30010,000 shares@ €3.330.025% mcap17.8% of flow
ActionEuronext Paris
2025DD1085381·
€119,99933,333 shares@ €3.6064.3% of flow
ActionEuronext Paris
2021DD800917·
3 of 3 declarations
About Christian Chavy
Christian Chavy is a seasoned executive in the pharmaceutical and biotechnology sectors, widely recognized for his international leadership experience across management, operations, and strategic development. As an independent director of ABIONYX Pharma, he brings deep healthcare industry expertise to the board, built through a career spanning several senior roles in major pharmaceutical groups and health-focused investment environments. ABIONYX Pharma’s corporate documentation states that he served as Chief Executive Officer of Stallergenes from March 2014 to March 2016, after joining ARES Life Science in 2010, an investment fund dedicated to healthcare. He also held the position of President of Global Operations at Actelion Pharmaceuticals, overseeing the United States, Europe, Japan, and the rest of the world. Earlier in his career, he was Vice President of Serono’s reproductive medicine strategic unit in Geneva and Chairman of Serono’s French subsidiary. His background also includes five years with Rhône-Poulenc Rorer, where he served as Chairman of Rorer Canada after previously acting as Chairman and CEO of Rorer France. A graduate of ESSEC and the Institut de Contrôle de Gestion in Paris (ICG), Christian Chavy combines industrial discipline, governance expertise, and a strong international outlook. For ABIONYX Pharma, a biotech company focused on the development of innovative therapies, his profile is especially valuable because it blends operational leadership, strategic judgment, and familiarity with highly regulated healthcare markets. His presence on the board supports robust oversight, long-term value creation, and strategic execution.